Evidence map›Paper›PMID 31463582›Full record

ReviewHerzschrittmachertherapie & Elektrophysiologie2019

[Cardiac arrhythmias in oncological diseases, during radiotherapy, chemotherapy].

Lorenz H Lehmann, Hugo A Katus, Eberhard P Scholz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herzschrittmachertherapie & Elektrophysiologie, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lorenz H LehmannAbteilung für Innere Medizin III, Kardiologie, Angiologie, Pneumologie, Sektion Kardio-Onkologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland. lorenz.lehmann@med.uni-heidelberg.de.
Hugo A KatusAbteilung für Innere Medizin III, Kardiologie, Angiologie, Pneumologie, Sektion Kardio-Onkologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland.
Eberhard P ScholzAbteilung für Innere Medizin III, Kardiologie, Angiologie, Pneumologie, Sektion Kardio-Onkologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with oncological diseases frequently show cardiac arrhythmias. This is explained by an increased risk in this specific patient cohort and is frequently associated with specific oncological therapies. So far, it is unclear how to deal with the occurrence of arrhythmias diagnostically and therapeutically, since the current clinical data do not provide satisfying answers to these questions. Clinical care of high-risk patients in specialized teams with a focus on cardio-oncology is recommended. Based on the current clinical studies and the position papers of the European Society of Cardiology (ESC), we give a brief overview of arrhythmias in malignant diseases and their therapies.

Indexed as

Arrhythmias, CardiacNeoplasmsCardiologyHumansArrhythmiasCardiac side effectsCardio-oncologyHigh-risk patientsMonitoring

Identifiers

PMID31463582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.